about
The anti-melanoma activity of dinaciclib, a cyclin-dependent kinase inhibitor, is dependent on p53 signalingCRAF inhibition induces apoptosis in melanoma cells with non-V600E BRAF mutationsDiscovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activityRewired ERK-JNK signaling pathways in melanomaBeyond BRAF: where next for melanoma therapy?Demonstration of a genetic therapeutic index for tumors expressing oncogenic BRAF by the kinase inhibitor SB-590885Similar Biological Activities of Two Isostructural Ruthenium and Osmium ComplexesStructure-Based Design of an Organoruthenium Phosphatidyl-inositol-3-kinase Inhibitor Reveals a Switch Governing Lipid Kinase Potency and SelectivityLigand internalization and recycling by human recombinant somatostatin type 4 (h sst(4)) receptors expressed in CHO-K1 cellsThe treatment of advanced renal cell cancer with high-dose oral thalidomideManaging leptomeningeal melanoma metastases in the era of immune and targeted therapy.The state of melanoma: challenges and opportunitiesResistance to Raf inhibition in cancer.Evaluating melanoma drug response and therapeutic escape with quantitative proteomicsA rare case of leptomeningeal carcinomatosis in a patient with uveal melanoma: case report and review of literature.Recovery of phospho-ERK activity allows melanoma cells to escape from BRAF inhibitor therapy.Bortezomib induces apoptosis in esophageal squamous cell carcinoma cells through activation of the p38 mitogen-activated protein kinase pathway.Molecular pathways: targeting NRAS in melanoma and acute myelogenous leukemia.Fibroblasts protect melanoma cells from the cytotoxic effects of doxorubicin.The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanismsChange or die: targeting adaptive signaling to kinase inhibition in cancer cells.A brief history of melanoma: from mummies to mutationsMethods for investigation of targeted kinase inhibitor therapy using chemical proteomics and phosphorylation profiling.Adhesion, migration and communication in melanocytes and melanoma.Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases.Inhibition of HSP90 by AT13387 delays the emergence of resistance to BRAF inhibitors and overcomes resistance to dual BRAF and MEK inhibition in melanoma modelsPTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expressionIdentification of BRAF mutations in eruptive melanocytic nevi: new insights into melanomagenesis?A pivotal role for ERK in the oncogenic behaviour of malignant melanoma?Up-regulated expression of zonula occludens protein-1 in human melanoma associates with N-cadherin and contributes to invasion and adhesion.Ligand-independent EPHA2 signaling drives the adoption of a targeted therapy-mediated metastatic melanoma phenotype.Amuvatinib has cytotoxic effects against NRAS-mutant melanoma but not BRAF-mutant melanoma.Phosphoproteomic analysis of basal and therapy-induced adaptive signaling networks in BRAF and NRAS mutant melanoma.Evaluating kinase ATP uptake and tyrosine phosphorylation using multiplexed quantification of chemically labeled and post-translationally modified peptides.The great escape: another way for melanoma to leave physiological control?Fibroblasts contribute to melanoma tumor growth and drug resistance.Using quantitative proteomic analysis to understand genotype specific intrinsic drug resistance in melanoma.The Novel ATP-Competitive MEK/Aurora Kinase Inhibitor BI-847325 Overcomes Acquired BRAF Inhibitor Resistance through Suppression of Mcl-1 and MEK ExpressionDysregulation of claudin-7 leads to loss of E-cadherin expression and the increased invasion of esophageal squamous cell carcinoma cellsTargeting mutant BRAF in melanoma: current status and future development of combination therapy strategies
P50
Q21133611-1002FB2B-3E9F-41B8-BABA-5CFFD9E5C5D2Q24618486-8C146D24-199C-43D3-A158-DD91C5B58C7CQ24652600-918ADABD-0417-4747-A4CD-63F25E282B75Q24683737-E54B8466-D4FD-4405-B7BA-154EA67CD265Q27006853-DDC9AB3F-AF7C-4D55-A3DD-BFFA77712828Q27643208-A7AF3751-924C-44DB-99C5-EE65A0D8951FQ27650404-FBD1C8E2-0DB3-4667-ADB8-1CE07EAFCEFCQ27650628-816DFCB1-9FD6-47DD-9642-7FB1DB7BEC45Q28354222-476F38FC-BA54-4222-A419-96B255E0D6BCQ28361231-8E4B1CDD-603B-4334-9EFD-0578FA27F17AQ30251581-F88FA279-165D-4B46-BD35-36391CF0CA82Q30276971-691F4E6E-CF09-44A1-B874-160AB990CB91Q33651779-46A424B4-6A10-457A-B9AE-1328A6C19EBFQ33850665-BBE3874C-B629-42B2-BC7C-AEF2C024EBF0Q33885560-F70B0425-E27F-4C7D-86C3-758D7C07C044Q33906093-5D51F77D-56C3-429B-8EC5-329EAE6F2EF9Q33989444-FCEC2B1F-7827-4BFB-A4DF-6664A63BE2ACQ34052520-1AF4815A-BC84-41E1-B5E7-1B1E782FA886Q34164261-2A0D0B0E-8B26-470E-883E-FF69E248BC25Q34165045-91BF3D35-1ED8-49C3-8102-6EDB29E7E322Q34225871-0DFDA9B8-01A8-4AF5-BFBD-875684E9E415Q34259205-9EF9A195-5E10-4EFE-B862-F44BA7C8E17EQ34373301-2A6E6342-CD40-454D-B6EE-E36CB45B6624Q34418722-0F42BF19-E2E3-4CF1-AFEA-CB25349E35BEQ34531564-B308800C-6612-44E3-AC5D-5D99828861DEQ34677194-FF31A0D9-8ECC-4B9E-9533-3C1AE4BA579BQ34761941-BF942CA7-6453-4FBD-BDD4-9B3FD40784C2Q35059440-ED633034-5047-4B98-983A-BD70D21B9F66Q35069175-91CAB17A-43A5-4A87-A0E1-ABF84B7047B9Q35087817-B93BAB19-D9D9-4675-80E0-B4DD07C31ED7Q35164121-8A647ABB-2F06-454C-B7EA-CC55CDD541B2Q35262625-118E51FB-D88A-4671-9DE4-01B59047F5F6Q35320304-219FC1D7-1ABD-44F2-BDF8-2477AE9C4FCDQ35579916-B9C1B036-C421-49F8-A2D4-D037A12E4FC0Q35590883-04513D5E-4321-47F2-8399-A445C9AE91B7Q35607701-0E795EF6-9BA7-4888-BEDE-175745D9F65FQ35640196-C9438066-2854-4D78-81A1-A99A8C4DB98EQ35691278-321B0B10-A07C-46AB-B5BD-B5B5B5CA3118Q35750120-830A65C3-C1AB-4EE6-A794-E3A40B842F8DQ35859282-3D864D29-CBFC-4645-886A-A370389FAA8B
P50
description
researcher ORCID ID = 0000-0003-1089-9307
@en
wetenschapper
@nl
name
Keiran S M Smalley
@ast
Keiran S M Smalley
@en
Keiran S M Smalley
@nl
type
label
Keiran S M Smalley
@ast
Keiran S M Smalley
@en
Keiran S M Smalley
@nl
prefLabel
Keiran S M Smalley
@ast
Keiran S M Smalley
@en
Keiran S M Smalley
@nl
P31
P496
0000-0003-1089-9307